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Abstract
Several large randomized clinical trials in North America and Europe concluded over a decade ago
that carotid endarterectomy plus medical management was significantly better than medical
management alone for stroke prevention in either symptomatic or asymptomatic patients with severe
carotid stenosis. Percutaneous carotid angioplasty now represents yet another treatment option that
currently appears to have a higher risk than endarterectomy in symptomatic patients as well as in
those who are 70 years of age or older. For these reasons, there is a consensus that angioplasty
should be used cautiously in such patients and probably remains most appropriate either in the
context of ongoing randomized trials or for patients who are at a higher-than-average risk for
conventional surgical treatment.
Introduction and context
Few modern clinical problems have provoked as much
controversy as extracranial carotid artery disease.
Prompted by concern that carotid endarterectomy
(CEA) was being performed for uncertain indications
during the 1980s, four randomized clinical trials (RCTs)
were sponsored by the National Institutes of Health in
the United States and by the Medical Research Council in
the United Kingdom in order to determine the benefit of
CEA in symptomatic patients and for asymptomatic
carotid stenosis. These included the North American
Symptomatic Carotid Endarterectomy Trial (NASCET)
[1,2], the European Carotid Surgery Trial (ECST) [3-5],
the Asymptomatic Carotid Atherosclerosis Study (ACAS)
[6] and the Asymptomatic Carotid Surgery Trial (ACST)
[7,8], all of which remain the foundation for proper
patient selection and should be thoroughly familiar to
clinicians who recommend or perform any kind of
carotid intervention.
Table 1 contains data from these four important
investigations. It must be noted that the methods for
estimating the percentage of carotid stenosis differed in
the North American (NASCET, ACAS) and the European
(ECST, ACST) trials. The former used the diameter of the
uninvolved internal carotid artery distal to the index
lesion as the denominator, whereas the latter employed
the projected normal diameter of the internal carotid
bulb. Nevertheless, the conclusions reached by these
trials were reasonably consistent and can be summarized
as follows.
First, the 30-day combined stroke or mortality rates for
CEA were two to three times higher in symptomatic
patients than in patients who had asymptomatic carotid
stenosis. This may reflect the potential of symptomatic
lesions to cause intraoperative cerebral emboli during
carotid manipulation.
Second, the benefit of CEA was greater and became
obvious within shorter periods of follow-up in patients
who had previous symptoms in conjunction with severe
carotid stenosis measuring at least 70% of lumen
diameter. The relative risk reduction associated with CEA
for 50–69% stenosis was only marginally significant
(P = 0.045) in the NASCET, and the ECST showed no
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patients.Somesymptomaticsubgroupsappearedtoderive
more benefit from CEA, including patients who were 75
years of age or older as well as those who had more than
90% stenosis, ulcerated plaques, or recent transient
ischemic attacks within 2 weeks of randomization [9].
Third, in comparison to symptomatic patients in the
NASCET and ECST, patients with asymptomatic carotid
stenosis in the ACAS and the ACST had lower long-term
event rates irrespective of whether they were allocated to
CEA or medical management. Furthermore, while CEA
provided a significant overall reduction of relative risk in
the ACAS,this benefit seemedsubstantiallyless impressive
in women than in men (17% versus 66%; P = 0.10),
probablybecausetheytendedtohaveahigherincidenceof
perioperativestrokeordeath(3.6%versus1.7%;P=0.12).
Fourth, the ACST did not substantiate the apparent
lesser benefit of CEA that was found in asymptomatic
women by the ACAS, but this might be related to the
fact that the ACST excluded the risk for perioperative
stroke or death (3.6% in women, 2.5% in men) from its
subset analyses. The ACST also reported that unoper-
ated patients with 60–79% stenosis were as likely as
those with 80–99% stenosis to have future strokes. The
ACAS had limited arteriographic data with which to
further stratify its criterion of 60–99% stenosis, but
other non-randomized case series have strongly sug-
gested that asymptomatic 60–79% stenosis has a very
low risk for stroke and can be kept under surveillance by
duplex scanning [10].
Fifth, the ‘number needed to treat’ (NNT) is defined as
the number of patients who would have to undergo CEA
in order to prevent one long-term adverse event. In the
NASCET, this ranged from an NNT of 6 for patients who
had 70–99% stenosis [1] to an NNT of 15 for patients
with 50–69% stenosis [1,2]. The corresponding NNT was
19 for all patients in the ACAS and undoubtedly was
even higher in women [6], while the NNT in the ACST
was 20 [8]. In summary, CEA must be performed in
substantially more asymptomatic patients before one
can gain the advantage of stroke prevention.
Recent advances
Percutaneous carotid angioplasty (PCA) was described in
isolated case reports during the late 1970s and has since
been the topic of more than 20 large case series, over a
dozen industry-sponsored registries, and several inde-
pendent trials [11]. Many of these studies became
obsolete almost immediately because of additional
refinements in endovascular technology, such as carotid
stents and over-the-wire cerebral embolic protection
devices [12]. Table 2 summarizes the results from six
RCTs that were published in peer-reviewed journals
[13-22] and frequently have been cited on the basis of
their timeliness or their controversial aspects, depending
on the perspective from which they are viewed [23].
CAVATAS
Conducted from 1992 to 1997, the Carotid and Vertebral
Artery Transluminal Angioplasty Study (CAVATAS) was
the earliest trial of PCA versus CEA to be independently
funded and to capture international attention. Each of
the participating centers had to designate one or more
radiologists with prior training in angioplasty techniques,
but there was no requirement for previous experience
with the carotid artery. The initial CAVATAS disclosures
revealed no outcome differences between PCA and CEA
Table 1. Selected data from influential randomized clinical trials (RCTs) comparing carotid endarterectomy versus medical management
for stroke prevention
RCT Severity of
stenosis (%)
30-day surgical
CSM (%)
Reported follow-
up period (yrs)
Long-term primary event rate Relative risk
reduction (%)
P value
Carotid
endarterectomy (%)
Medical
management (%)
Symptomatic
patients
NASCET [1] 70-99 5.8 2 9.0
a 26.0
a 65 <0.001
NASCET [2] 50-69 6.7 5 15.7
a 22.2
a 29 0.045
ECST [3] 70-99 7.5 3 12.3
b 21.9
b 45 <0.01
ECST [4,5] 50-69 7.9 8 18.4
b 15.6
b None –
Asymptomatic
patients
ACAS [6] 60-99 2.3 5 5.1
a 11.0
a 53 0.004
ACST [7] 60-99 3.1 5 6.4
c 11.8
c 46 <0.0001
ACST [8] 60-99 3.1 10 13.4
b 17.9
b 25 0.009
aDeath or stroke within 30 days and subsequent ipsilateral strokes.
bDeath or stroke within 30 days and all subsequent strokes.
cStroke (but not death)
within 30 days and all subsequent strokes. ACAS, Asymptomatic Carotid Atherosclerosis Study; ACST, Asymptomatic Carotid Surgery Trial; CSM,
combined stroke and/or mortality rate; ECST, European Carotid Surgery Trial; NASCET, North American Symptomatic Carotid Endarterectomy Trial.
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erodedbya30-daystrokeormortalityrateforCEA(9.9%)
that was much worse than generally had been reported.
Moreover, carotid stents were used in only 26% of the
patients who received PCA, a factor that could have
contributedtoahighincidenceofrecurrent≥70% stenosis
(18% versus 5.2% for CEA; P = 0.0001) at just 1 year of
follow-up [24]. Cerebral embolic protection devices were
unavailable at that time, so this adjunct was not used in
the CAVATAS. For these reasons, the CAVATAS has
become relatively obsolete despite the fact that it remains
theonlyRCTofitskindtoreportresultsaslongas10years
after PCA [14].
SAPPHIRE
The Stenting and Angioplasty with Protection in Patients
at High Risk for Endarterectomy (SAPPHIRE) trial was
funded by industry and for this reason may not have
quite the cachet of an independent RCT. It enrolled
asymptomatic patients with ≥80% stenosis in addition to
symptomatic patients with ≥50% stenosis, and it
employed a unique primary end point of stroke, death,
and/or myocardial infarction (MI). This represented a
departure from the traditional composite end point of
stroke and/or death, especially since it included asymp-
tomatic elevations in cardiac isoenzyme and troponin
levels that had not been measured in most previous
studies of CEA. The SAPPHIRE trial did have a number of
practical features, however. First, it only accepted
patients who were less than ideal surgical candidates
because of such things as serious cardiac (e.g., recent MI
or unstable angina, congestive heart failure, or <30%
ejection fraction) or pulmonary disease, advanced age
(80 years or older), contralateral internal carotid occlu-
sion, or treacherous local anatomy (caused by high
carotid lesions near the skull base, a history of cervical
irradiation, or recurrent stenosis after prior CEA).
Second, interventionalists were strictly vetted and had a
median past experience of 64 PCAs. Third, every PCA
procedure was done using a cerebral embolic protection
device and a carotid stent, both of which were
manufactured by the sponsor (Cordis Corporation).
Much of the difference in 30-day end points could be
attributed to a higher incidence of ‘chemical’ MIs after
CEA, but the ultimate conclusion of the trial was that
PCA provided an equivalent alternative in patients who
were perceived to be at high risk for CEA. The SAPPHIRE
trial has been criticized on the grounds that the majority
(70%) of its patients were asymptomatic, that too many
were entered into a non-randomized PCA registry
because they were considered unsuitable for CEA, and
that the unconventional primary end points were
potentially misleading [25]. However, asymptomatic
carotid disease is the most common indication for CEA
or PCA in the United States [26] – and not just for the
Table 2. Selected data from major multicentered randomized clinical trials (RCTs) comparing carotid endarterectomy to percutaneous
carotid angioplasty
RCT Clinical features Angioplasty
adjuncts
30-day primary outcome
event rates
Long-term primary outcome event rates
Symptoms
(%)
Stenosis
(%)
Stent
(%)
CEP
(%)
CEA
(%)
PCA
(%)
P value CEA
(%)
PCA
(%)
P value
CAVATAS
[13,14]
97 Mean, 85±10 26 None 9.9
a 10
a NS 14.2
b (3 years)
50.4±4.1
a
(8 years)
14.3
b (3 years)
45.2±4.0
a (8 years)
0.9
SAPPHIRE
c
[15,16]
29 ≥50 (symptomatic);
≥80 (asymptomatic)
100 100 9.8
d 4.8
d 0.09 20.1
e (1 year)
30.3
e (3 years)
12.2
e (1 year)
26.2
e (3 years)
0.05
0.71
SPACE [17,18] 100 ≥50% (NASCET);
≥70% (ECST)
100 27 6.3
f 6.8
f 0.09 8.8
g 9.5
g 0.62
EVA-3S [19,20] 100 ≥60% 100 92 3.9
h 9.6
h 0.01 4.2
i (6 months)
6.2
i (4 years)
10.2
i (6 months)
11.1
i (4 years)
0.008
0.03
ICSS [21] 100 ≥50% 92 72 4.0
d 7.4
d 0.003 5.2
j 8.5
j 0.006
CREST [22] 53 ≥50 (symptomatic)
≥60 (asymptomatic)
100 94 4.5
d 5.2
d 0.38 6.8
k 7.2
k 0.51
aDeath or stroke.
bDeath or disabling stroke.
cIndustry sponsored (Cordis Corporation).
dDeath, stroke, or myocardial infarction.
eDeath, stroke, or
myocardial infarction within 30 days or subsequent ipsilateral stroke.
fDeath or ipsilateral ischemic stroke.
gDeath or stroke within 30 days or ipsilateral
ischemic stroke within 2 years.
hAny death or stroke.
iAny death or stroke within 30 days or subsequent ipsilateral stroke.
jDeath, stroke, or myocardial
infarction within 120 days of randomization.
kDeath, stroke, or myocardial infarction within 30 days or death or ipsilateral stroke within 4 years. CAVATAS,
Carotid and Vertebral Artery Transluminal Angioplasty Study; CEA, carotid endarterectomy; CEP, cerebral embolic protection; CREST, Carotid
Revascularization Endarterectomy versus Stenting Trial; ECST, European Carotid Surgery Trial criteria; EVA-3S, Endarterectomy Versus Angioplasty in
Patients with Symptomatic Severe Carotid Stenosis trial; ICSS, International Carotid Stenting Study; NASCET, North American Symptomatic Carotid
Endarterectomy Trial criteria; PCA, percutaneous carotid angioplasty; SAPPHIRE, Stenting and Angioplasty with Protection in Patients at High Risk for
Endarterectomy trial; SPACE: Stent-Supported Percutaneous Angioplasty of the Carotid Artery versus Endarterectomy trial.
Page 3 of 7
(page number not for citation purposes)
F1000 Medicine Reports 2010, 2:91 http://f1000.com/reports/m/2/91convincing severity of stenosis (80–99%) that this trial
required. In addition, participating surgeons may have
been understandably reluctant to randomly assign
certain patients who had multiple high-risk factors for
CEA. Finally, although the inclusion of clinically
unsuspected MIs was a novel approach to early outcome
assessment, it is difficult to argue logically that these
events should have been allowed to go undetected.
Nevertheless, if the 30-day analysis had included only
the previously conventional endpoints of stroke or death
(5.5% for PCA versus 8.4% for CEA), the difference
between the treatment groups would not have been
statistically significant at either 1 year [15] or 3 years [16]
of follow-up.
SPACE
The Stent-Supported Percutaneous Angioplasty of the
Carotid Artery versus Endarterectomy (SPACE) trial is a
non-inferiority study that was designed to demonstrate
equivalence between PCA/stenting and CEA. In order to
participate, interventionalists had to show proof of at
least 25 successful consecutive PCA procedures. The
virtues of the SPACE trial are its large size (1200
symptomatic patients), which exceeded any previous
RCT, and the fact that it was supported predominantly by
independent resources. Its perceived liabilities are that
cerebral embolic protection was used during only 27% of
the PCA procedures and that recruitment was prema-
turely stopped for lack of funding after it was discovered
that more than 2500 patients would be necessary to
confirm its interim results with adequate statistical
power. At that time, the 30-day risk for death or
ipsilateral stroke appeared comparable for PCA and
CEA (6.8% and 6.3%, respectively), but the P value for
non-inferiority was only 0.9. No long-term event rates
were available in the original report of the SPACE trial
[17], but they now have been reported at 2 years of
follow-up by Eckstein et al. [18].
EVA-3S
The Endarterectomy Versus Angioplasty in Patients with
Symptomatic Severe Carotid Stenosis (EVA-3S) trial
could conceivably serve as a proxy for the evolution of
PCA in other large population bases. Sponsored by the
French Ministry of Health in 20 academic and 10 non-
academic medical centers, this trial permitted the use of
a variety of approved catheter devices. Carotid stenting
was mandatory, but cerebral embolic protection (ulti-
mately used in 92% of patients) was not routinely
recommended until the 30-day stroke rate was dis-
covered to be 3.9 (95% confidence interval [CI]
0.9–16.7) times higher without embolic protection
(27%, 4 out of 15 patients) than with protection
(8.6%, 5 out of 58 patients) in the initial 73 patients
treated by PCA [27]. Perhaps the most controversial
element of this trial is that interventionalists who had
no previous experience with PCA still were permitted to
perform it in randomly assigned patients under the
supervision of tutors until they acquired the requisite
number of 12 PCAs (or only 5 PCAs plus another
30 stenting procedures in aortic arch vessels) for full
accreditation. (Interventionalists also could begin using
a new catheter device within the trial as soon as they
had gained some familiarity with it in just two other
cases.) Despite this controversy, however, there was no
significant difference between experienced intervention-
alists and those who were tutored either during or after
their training with respect to 30-day combined stroke
and mortality rates (10% versus 7.1% versus 12%;
P = 0.54).
Trial enrollment was stopped on the basis of safety and
futility once the 30-day stroke or mortality rate in the first
527 treated patients was found to be so much higher for
PCA than for CEA (9.6% versus 3.9%; relative risk 2.5;
95% CI 1.2–5.1; P = 0.01) that more than 4000 patients
would have been necessary to demonstrate its non-
inferiority to CEA. Largely on the basis of its lower
operative risk, the results of CEA have remained superior
to those of PCA from 6 months [19] to 4 years [20] of
follow-up. The EVA-3S trial has been criticized for the
inexperience among its interventionalists and the lack of
a standardized technique for PCA, but the flaws that
some might find in this trial – the blend of community
hospitals as well as referral centers, the mid-course
changes to new or improved equipment, and the low
procedural volumes or on-the-job training by more
experienced colleagues – probably are ubiquitous and
may make its results even more relevant to ‘real world’
practice [28]. The French trial was restricted to sympto-
matic patients, but another national dataset also showed
that PCA/stenting was associated with higher risks for
stroke or death than CEA in either symptomatic or
asymptomatic patients in the United States during 2003
and 2004 [26].
ICSS
An interim analysis of the International Carotid Stenting
Study (ICSS), a large trial comprising 1713 symptomatic
patients, has reported results at a maximum of 120 days
following CEA or PCA (nearly all of the PCAs used stents
and cerebral protection devices) [21]. Surgeons had to
have performed at least 50 carotid operations, and
interventionalists who had not done a minimum of 10
carotid stenting procedures were proctored until they
had completed a total of 20 acceptable cases within the
trial. Among patients who actually received the treatment
to which they had been assigned, the 30-day risk for
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than after CEA (7.4% versus 4.0%; relative risk 1.8; 95%
CI 1.2–2.8; P = 0.003). Only four MIs occurred in the
CEA group, none of which was fatal. On the basis of an
intention-to-treat analysis, the 120-day risk for stroke,
death, or MI still was higher in the PCA cohort (8.5%
versus 5.2%; P = 0.006). Furthermore, in a subset of 231
patients who underwent diffusion-weighted magnetic
resonance imaging both before and after carotid inter-
vention [29], new ischemic brain lesions were docu-
mented far more frequently in the PCA group than in the
CEA group (50% versus 17%; adjusted odds ratio 5.2;
95% CI 2.8–9.8; P < 0.0001). Follow-up scans done
1 month later showed that these changes persisted in
33% of the patients who had PCA compared to only 8%
of those who had CEA.
Neither the ICSS nor the SPACE or EVA-3S trials had
sufficient statistical power to determine whether PCA
might be an appropriate alternative to CEA in certain
subgroups of symptomatic patients, but a collaborative
preplanned meta-analysis of individual patient data
from these three RCTs has now been conducted to
address this issue [30]. Of the 16 variables that were
assessed (such as age, gender, prior symptoms, the
severity of ipsilateral and contralateral carotid stenosis,
and hospital volume of PCA) only age proved to be a
significant factor in a total of 3324 patients who had
their allocated procedure. Among those who were
younger than the median age of 70 years, the 30-day
incidence of stroke or death was comparable for PCA and
CEA (5.1% and 4.5%, respectively). In patients who were
70 years of age or older, however, the risk of stroke or
death for PCA was over twice that for CEA (10% versus
4.4%; risk ratio 2.4; 95% CI 1.6–3.5; P = 0.0078). Others
also have found that PCA has a higher serious
complication rate in older patients, probably because
of the potential for catheter-directed devices to provoke
cerebral emboli in the presence of the arterial tortuosity
and calcification that often occur in the elderly [31-33].
CREST
The Carotid Revascularization Endarterectomy versus
Stenting Trial (CREST) is the largest RCT comparing PCA
to CEA yet to be reported, enrolling 1321 symptomatic
and 1181 asymptomatic patients at 117 centers from
2000 to 2008 [22]. All PCA procedures were done with a
stent, and cerebral embolic protection was employed in
94% of patients. The CREST trialists used a composite
primary end point defined as any periprocedural stroke,
death or MI, or an ipsilateral stroke within 4 years of
randomization, but they also provide data regarding
stroke and death alone. According to an intention-to-
treat analysis at a median follow-up interval of 2.5 years,
the estimated 4-year primary end point rate was
equivalent for carotid artery stenting and CEA (7.2%
versus 6.8%). This effect was not influenced by the
symptomatic status (P = 0.84) or patient gender (P =
0.34), but there was a crossover point leading to
significantly higher risks for PCA in patients aged 70 or
older (P = 0.02), as was the case in the collaborative
meta-analysis of the ICSS, SPACE, and EVA-3S trials [30].
Whereas the 30-day incidence of MI was higher with CEA
(2.3% versus 1.1%; P = 0.03) in the CREST, early strokes
occurred more frequently with PCA (4.1% versus 2.3%;
P = 0.01). Finally, a prespecified secondary analysis
indicated that PCA had a higher 4-year stroke or death
rate than CEA (6.4% versus 4.7%; risk ratio 1.5; 95% CI
1.1–2.1; P = 0.03). By comparison, PCA in the CREST
was associated with a lower periprocedural stroke or
death rate than any of the other RCTs in Table 2 except
the SAPPHIRE trial. In this regard, it must be noted that
both of these studies included a substantial number of
asymptomatic patients.
Implications for clinical practice
Citing much of the material covered in this review as well
as additional sources in the literature, the Society for
Vascular Surgery [34] and the European Society for
Vascular Surgery [35] have published practice guidelines
for the management of atherosclerotic carotid artery
disease. These documents reconfirmed the continued
importance of the NASCET, ECST, ACAS, and ACST in
the selection of patients for either surgical or catheter-
based intervention, emphasizing that patients who have
symptomatic <50% stenosis or asymptomatic <60%
stenosis are well suited to optimal medical management
alone. Each of the societal guidelines also suggests that
CEA plus best medical therapy should remain the
primary option for patients with more severe stenosis
unless the ICSS and the CREST were to prove otherwise.
In fact, the recently published conclusions from the ICSS
and the CREST are decidedly mixed. Although both agree
that PCA is associated with a higher risk for stroke or
death in patients 70 years of age or older, the CREST has
not confirmed the significant risk of PCA in symptomatic
patients that was found in the ICSS. On the basis of these
uncertainties, PCA generally seems to be most appro-
priate in the setting of ongoing RCTs until it has been
shown conclusively to be at least as safe and durable as
CEA in certain patient subsets. In the meantime,
exceptions favoring PCA can be justified for patients
whose medical comorbidities or cervical anatomy make
them questionable candidates for CEA.
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